What’s the current market cap for Surgery Partners stock?

Surgery Partners (SGRY) has a market cap of $1.8B as of June 03, 2026.

What is the P/E ratio for Surgery Partners stock?

The price to earnings (P/E) ratio for Surgery Partners (SGRY) stock is 0 as of June 03, 2026.

Does Surgery Partners stock pay dividends?

No, Surgery Partners (SGRY) stock does not pay dividends to its shareholders as of June 03, 2026.

When is the next Surgery Partners dividend payment date?

Surgery Partners (SGRY) stock does not pay dividends to its shareholders.

What is the beta indicator for Surgery Partners?

Surgery Partners (SGRY) has a beta rating of 1.99. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Surgery Partners stock | $SGRY Share Price

13:30

15:10

16:45

18:25

20:00

About Surgery Partners

Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities, which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earn revenues from contracts with patients in which the performance obligations are to provide health care services.

Ticker

$SGRY

Sector

Health

Primary listing

NASDAQ

Employees

16,000

Headquarters

Brentwood, United States

Website

www.surgerypartners.com

Surgery Partners Metrics

BasicAdvanced

$1.8bn

-$0.60

1.99

What the Analysts think about Surgery Partners

Analyst ratings (Buy, Hold, Sell) for Surgery Partners stock.

Bulls say / Bears say

Surgery Partners posted adjusted EPS of -$0.03 for Q1 2026, beating the consensus estimate of -$0.15 by $0.12 (Reuters)

The company reported first-quarter 2026 revenue of $810.9 million, a 4.5% increase from the prior year, and maintained its full-year 2026 revenue outlook of $3.35 billion to $3.45 billion (Reuters)

Surgery Partners acquired Preferred Vascular Group in March 2026, gaining entry into the $6 billion dialysis access market and expanding its surgical service offerings (StreetInsider)

Surgery Partners’ adjusted EBITDA in Q3 2025 increased 6.1% year-over-year to $136.4 million but fell short of analyst expectations, pointing to continued margin pressure (Reuters)

In November 2025, Surgery Partners lowered its full-year 2025 revenue forecast to $3.275 billion–$3.30 billion and reduced its Adjusted EBITDA guidance to $535 million–$540 million, citing lower procedure volumes and unfavorable payor mix (Reuters)

Despite operational progress, the company reported a net loss of $35.9 million in Q1 2026, highlighting ongoing GAAP profitability issues (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 21 May 2026.

Surgery Partners Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Surgery Partners Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SGRY

Capital at risk

Market open

Upcoming events

No upcoming events